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Uromodulin bound with high affinity to human tumour necrosis factor (TNF) coated on microtitre plates. 
This interaction was not competitively inhibited by native TNF in solution. No interaction was observed 
between immobilized uromodulin and TNF in the liquid phase unless conditions were chosen which dena- 
tured the latter protein. Recombinant interleukin-la adsorbed on microtitre plates also interacted with uro- 
modulin. However, gel filtration experiments demonstrated no interaction between the proteins in the liquid 
phase. These and additional results indicate that uromodulin interacts with denatured cytokines, but not 
with native, soluble cytokines. 
Uromodulin; Tamm-Horsfall glycoprotein; Interleukin-1; Tumour necrosis factor 
1. INTRODUCTION 
Uromodulin isolated from the urine of pregnant 
women, has been described as a unique 85 kDa im- 
munosuppressive glycoprotein [ 11. The N-linked 
oligosaccharides were proposed to be the im- 
munosuppressive component [2,3]. TH-glyco- 
protein is the most abundant protein of renal 
origin in normal urine but a physiological role for 
this protein has not been established [4]. The 
primary structure of uromodulin, recently deter- 
mined from the cDNA clone [5,q, may be iden- 
tical to that of TH-glycoprotein [5]. Both proteins 
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are isolated as high molecular mass aggregates with 
molecular masses > 1 x 106 Da [1,7]. 
Brown et al. [8] suggested that the immunosup- 
pressive properties of uromodulin are related to its 
ability to act as an inhibitor of IL-I. As we have 
discussed elsewhere [9], the apparent inhibition of 
the IL-l lymphocyte activating factor assay by 
uromodulin [8] is probably an artefact unrelated to 
specific effects on IL-l. It has been reported using 
a solid-phase binding assay [6,10,1 l] that 
uromodulin binds IL-1~ and TNF with high affini- 
ty. Here we have characterized this assay in more 
detail and provide evidence that uromodulin and 
TH-glycoprotein do not interact with soluble 
native cytokines. 
2. MATERIALS AND METHODS 
2.1. Proteins 
TH-glycoprotein was purified from urine pools 
of two males and uromodulin from urine pools of 
two pregnant females (second and third trimester). 
The procedure described below was used for both 
proteins. Urine (2 1) was adjusted to pH 6.0 and 
NaCl (33.6 g/l) was added. The cloudy solution 
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was left overnight at 4°C and then centrifuged at 
15ooO x g for 60 min. The pellet was resuspended 
with phosphate-buffered saline (PBS), pH 7.5, 
containing additional 0.58 M NaCl and centri- 
fuged. The pellet was dissolved in 50 mM Tris- 
maleate, pH 7.2 (buffer A), containing 8 M urea, 
dialyzed against buffer A containing 10% (w/v) 
ethyleneglycol and applied to a Fractogel TSK-65 
(s) (Merck, Darmstadt) column 60 cm x 5 cm 
diameter, equilibrated in buffer A containing 10% 
ethyleneglycol. Uromodulin and TH-glycoprotein 
eluted in the void volume. Proteins were concen- 
trated by ultrafiltration and dialyzed against 3-fold 
diluted PBS. About 25 mg uromodulin or TH- 
glycoprotein were obtained. 
Recombinant human IL-la was purified from 
E. coli as described [12]. Recombinant human 
TNF, recombinant human GM-CSF and HBcAg 
were from Biogen (Cambridge, USA). Aldolase 
was obtained from Sigma. 
2.2. Solid-phase binding assay 
The procedure described by Muchmore and 
Decker [ 10,l l] was followed with minor modifica- 
tions. Briefly, flat bottom micro-ELISA plates 
made of Immulon (Dynatech, Plochingen, FRG) 
were coated by overnight incubation at 4°C with 
protein solutions (100 &well) l-20 pg/ml in 
0.1 M carbonate buffer, pH 9.6 (unless otherwise 
stated). Control wells were incubated with buffer 
alone. Plates after protein coating, and other 
described incubations, were washed with PBS con- 
taining 0.05% (w/v) Tween 20 (PBWTween). 
Coating of the plates was checked with antibody 
against the coated protein. Uromodulin or TH- 
glycoprotein (0.003-3 pg/ml in PBWTween) were 
added in duplicate (100 pi/well) to coated and non- 
coated wells and the plates incubated at 37°C for 
2 h. In competition experiments, a solution of the 
protein used to coat the plates was also added. The 
plates were washed and anti-uromodulin (100 ~11 
well of a 500-fold dilution) added. After incu- 
bation for 1 h at 37°C and washing, peroxidase- 
labelled goat anti-rabbit IgG (Kirkegaard and 
Perry, Gaithersburg, MD) diluted lOOO-fold in 
PBS/Tween was added (100 pi/well) and the plates 
incubated for a further 1 h at 37°C. Colour 
development was made by the addition of 0.1% 
(w/v) 2,2’-amino-di-[3-ethyl-benzthiozoline sulfo- 
nate] (Boehringer, Marmheim) in 50 mM sodi- 
urn citrate, pH 4.8, containing 0.1% (v/v) of 
30% H202. Absorbances at 630 nm were measured 
using a Dynatech MR 580 micro-ELISA 
autoreader. The absorbances of control non- 
coated wells were subtracted from corresponding 
coated wells. 
2.3. Other methods 
IL-la was iodinated with mono-iodo-Bolton 
Hunter reagent as previously described [ 131. The 
radiolabelled IL-la had a specific radioactivity of 
1500 Ci/mmol and normal activity in an in vitro 
IL-l receptor binding assay [14]. For gel filtration 
experiments, uromodulin or TH-glycoprotein 
(20 pg) in buffer B (PBS/Tween containing 0.01% 
(w/v) bovine serum albumin and 0.02% (w/v) 
sodium azide), were premixed with [1251]IL-lu 
(10’ cpm) in a volume of 0.5 ml for 2 h at 37°C 
and applied to a 28 cm x 1 cm diameter column of 
TSK-65 (s) equilibrated with buffer B. For some 
experiments, buffer B also contained [‘251]IL-lcu 
(25 000 cpm/ml). 
Antibodies against proteins used were obtained 
from New Zealand white rabbits after immuniza- 
tion at multiple sites intradermally. Polyacryl- 
amide gel electrophoresis in the presence of SDS 
was performed as described [15]. Sedimentation 
velocity ,and fluorescence measurements were per- 
formed as previously described [16]. 
3. RESULTS AND DISCUSSION 
3.1. Characterization of uromodulin (TH- 
glycoprotein) 
Uromodulin and TH-glycoprotein gave single 
bands (Mr = 85000) when analysed by SDS-PAGE 
followed by Coomassie blue staining. N-terminal 
sequence analysis of TH-glycoprotein indicated 
two N-termini: Asp (75%) and Thr (25%). The 
results of 14 cycles of Edman degradation in- 
dicated a major sequence starting with Asp which 
was in exact agreement with that predicted by the 
cDNA sequence for mature uromodulin [5,6]. The 
N-terminal Thr gave rise to a sequence plus one 
residue out of phase with the main sequence. 
3.2. Interaction of uromodulin (TH-glycoprotein) 
with TNF 
The interaction of uromodulin with TNF was 
studied by the solid-phase binding assay. A strong 
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interaction was observed between TNF coated on 
plastic and uromodulin added in solution (fig.1); 
half-maximal binding of uromodulin occurred at 
about 0.1-0.075 pg/ml. Hession et al. [6] have 
recently reported a similar finding. The interaction 
was highly dependent on the type of microtitre 
plate used. For example, only a weak interaction 
was observed when Nunc-Immo microtitre plates 
(Nunc, Raskilde, DK) were used instead of the Im- 
mulon plates (fig.1). The coating of TNF to both 
types of plate was similar as estimated with anti- 
TNF. Contrary to the above results, TNF in solu- 
tion at neutral pH did not bind to uromodulin im- 
mobilized on Immulon microtitre plates (fig.2). 
However, at acidic pH a strong interaction was 
observed with half-maximal binding occurring at 
about pH 4.75-4.50 (fig.2). TNF at acid pH 
undergoes limited protein unfolding and aggrega- 
tion which can be monitored by changes in tryp- 
tophan fluorescence and the sedimentation 
coefficient (szo,,,) [161. Under acid conditions, the 
fluorescence peak emission wavelength of TNF 
red-shifts from 320 nm to 345 nm with a concomi- 
tant decrease in fluorescence intensity. This change 
in fluorescence, which titrates with an apparent 
pK, of 4.5 (fig.2), is due to solvent exposure of 
buried tryptophan residues accompanying protein 
unfolding. Protein aggregation at acid pH was in- 
dicated by large increases in the SZO,~ value (fig.2). 
Mouse TNF which shares a high degree of se- 
quence similarity with human TNF [17] rapidly 
loses its in vitro biological activity under acid con- 
ditions [ 181. This fact, together with the above fin- 
dings suggest that uromodulin interacts more 
strongly with aggregated/denatured, and 
presumably inactivated, TNF than with native pro- 
tein. The strong interaction between surface- 
adsorbed TNF and uromodulin in solution (fig.1) 
is consistent with this conclusion since adsorption 
of proteins to plastic surfaces can, depending on 
the stability of the protein, lead to denaturation 
and aggregation [191. The nature of the plastic sur- 
face might be expected to influence this process 
(fig. 1). 
Further support for the non-specific nature of 
the uromodulin-TNF interaction was obtained by 
competition studies in which uromodulin and TNF 
at neutral pH (0-lO~g/well) were added sequen- 
tially to microtitre plates coated with TNF. The 
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Fig. 1. Binding of uromodulin to TNF-coated Immulon 
(0) or Nunc-Immuno (A) micro-ELISA plates and of 
Tamm-Horsfall glycoprotein to TNF-coated Immulon 
plates (*). The plates were coated by overnight 
incubation with 100 ng TNF/well in buffer, washed and 
processed as described in section 2. 
concentrations tested to inhibit the binding of 
uromodulin to immobilized TNF again indicates 
that native TNF does not bind to uromodulin. 
3.3. Interaction of uromodulin (TH-glycoprotein) 
with IL-la 
Muchmore and Decker [lo] found that 
uromodulin binds with high affinity (K,, = 3 x 
lo-” M) to surface coated recombinant murine 
IL-10 (the characteristics of the IL-lcu preparation 
used were not reported). Using a well characterized 
preparation of human IL-la [12] we have been 
unable to reproduce this result although we did 
observe some interaction (Kd > 10m9 M). On the 
other hand, when uromodulin was immobilized, 
no interaction with IL-la in solution was observed 
over a wide range of protein concentration (not 
shown). There was also no interaction between 
IL-la and uromodulin when both proteins were in 
the liquid phase. Thus, preincubated mixtures of 
uromodulin and IL-la subjected to size exclusion 
chromatography (see section 2) resolved into pro- 
tein eluted in the void volume (uromodulin) and 
protein eluted with an apparent Mr of 18000 
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Fig.2. The pH-dependent interaction of soluble TNF 
with uromodulin-coated Immulon-plates (II). The 
changes in the sedimentation coefficient, ~20,~ (A) and 
fluorescence emission intensity at 317 nm (*) as 
functions of pH are also indicated. The microtitre plate 
was coated with 250 ng uromodulin/well, washed with 
PBS/Tween and then incubated with 100 ng TNF/well 
in PBS (pH 7.5) or in 0.1 M sodium acetate buffers with 
pH ranging from 4.0 to 6.5 for 2 h at 37°C. 
(IL-la). SDS-PAGE and Western blot analysis of 
column fractions, indicated no co-elution of IL-la 
and uromodulin. Also, the elution volumes of the 
separated proteins were the same as when they 
were chromatographed individually. To measure 
possible weak interactions, a mixture of 
uromodulin and IL-la were applied to a column 
pre-equilibrated with buffer containing radio- 
labelled IL-la (see section 2). Column fractions 
containing uromodulin had the same specific 
radioactivity as the starting column buffer in- 
dicating that no binding of IL-la to uromodulin 
had occurred. These results indicate that 
uromodulin interacts with surface-bound IL-ICY 
but not with the native protein in solution. 
3.4. Interaction of uromodulin (TN-glycoprotein) 
with other proteins 
Rabbit muscle aldolase is a tetrameric protein 
which, analogous to trimeric TNF, rapidly inac- 
tivates at pH values below 5 due to protein un- 
folding [20]. Microtitre plates were coated with 
aldolase at pH 9.6 (native state) and at pH 3.5 (un- 
folded state). Protein coated at either pH showed 
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Fig.3. Binding of uromodulin to plates coated with 
various proteins. HBcAg ( q ) and TNF (A) were coated 
at 100 ng and 2 fig/well, respectively. Aldolase was 
coated at 300 ng/well in pH 7.0 (*) and pH 4.0 (0) 
buffer. 
(fig.3). The binding affinity was similar to that ob- 
tained with immobilized TNF (fig.1). 
Uromodulin bound with a lOO-fold lower affini- 
ty to immobilized hepatitis core antigen (HBcAg) 
(fig.3). HBcAg is a multimeric complex which is 
extremely resistant to pH and protein chaotrope- 
induced denaturation (unpublished, P.W.) and is, 
therefore, less likely to denature upon adsorption 
to plastic surfaces than, for example, TNF. 
Recombinant GM-CSF purified from E. coli is a 
monomeric protein containing two intramolecular 
disulphide bonds [21]. Reduction of disulphide 
bonds with dithiothreitol leads to protein un- 
folding and aggregation (unpublished, P.W.). 
When native and reduced GM-CSF were separately 
coated on microtitre plates, only the latter bound 
uromodulin; the binding affinity was similar to 
that observed with TNF (fig.1). 
4. CONCLUSIONS 
Uromodulin and TH-glycoprotein behaved 
similarly to each other in all the binding assays 
described here, adding further support for the 
identity of these two proteins. (Uromodulin sup- 
plied by Dr A.V. Muchmore [l] behaved similarly 
to the uromodulin used here.) Both proteins did 
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not bind in solution to the cytokines tested namely, 
IL-la and TNF, but did interact with these pro- 
teins when they were adsorbed on plastic, that is, 
under conditions where they are likely to be un- 
folded and aggregated. The ‘assay-specificity’ of 
monoclonal antibodies has also been shown to be 
related to whether proteins are coated on solid sur- 
faces or are in solution [22]. The high affinity 
binding of uromodulin to proteins unrelated to the 
above mentioned cytokines namely, aldolase and 
to a lesser degree HbcAg, also point to the non- 
specific nature of this interaction. 
The lack of affinity in solution between 
uromodulin/TH-glycoprotein and IL-la is also 
consistent with the following observations: (a) the 
glycoproteins have no i~ibitory effect on co- 
stimulus independent bioassays for IL-l (un- 
published, P.M.); (b) uromodulin has no effect on 
the receptor-binding affinity of IL-la (Winger, L., 
personal communication); and (c) IL-l@ im- 
mobilized under mild conditions to Sepharose 4B 
(using Tresyl activated Sepharose) fails to bind 
uromodulin from solution (Muchmore, A.V., per- 
sonal communication). These observations, 
together with the findings reported here, strongly 
suggest hat native cytokines namely, IL-lc~, TNF 
and GM-CSF, do not bind to urom~ulin (TH- 
glycoprotein). Uromodulin is, therefore, unlikely 
to be an inhibitor of soluble IL-l. 
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